Other GLP-1-related therapies currently available for the treatment of type 2 diabetes are the once-daily GLP-1 receptor agonist, liraglutide, and the once-daily DPP-4 inhibitors sitagliptin and saxagliptin [31-33]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.